JW (Cayman) Therapeutics Co. Ltd
HKSE: 2126.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Min Liu
- Employees
- 281
- Headquarters
- Shanghai, China
- IPO year
- 2020
- Market cap
- HK$1.1B
- Website
- https://www.jwtherapeutics.com
Loading 2126…
Loading profile data…Frequently asked questions about 2126
What does JW (Cayman) Therapeutics Co. Ltd (2126.HK) do?
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight canc...
Where does 2126.HK trade?
JW (Cayman) Therapeutics Co. Ltd (2126.HK) trades on the Hong Kong Stock Exchange.
What sector is 2126.HK in?
JW (Cayman) Therapeutics Co. Ltd (2126.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of JW (Cayman) Therapeutics Co. Ltd?
Min Liu is the chief executive officer of JW (Cayman) Therapeutics Co. Ltd (2126.HK).
Where is JW (Cayman) Therapeutics Co. Ltd headquartered?
JW (Cayman) Therapeutics Co. Ltd is headquartered in China.
Does 2126.HK pay a dividend?
JW (Cayman) Therapeutics Co. Ltd (2126.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2126.HK go public?
JW (Cayman) Therapeutics Co. Ltd (2126.HK) completed its initial public offering in 2020.